|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
|
Fig. 6. Pharmacological inhibition of ALK5 with SB-431542 impaired TGF-
-induction of the ET-1 gene. Validation of compound SB-431542 (5 nM-10 µM) was done in BAEC transfected with (A) ALK1- and (B) ALK5-specific luciferase reporters together with ALK1 constitutively active (ca) and ALK5 ca forms, respectively. ET-1 mRNA levels, peptide accumulation and promoter activity were also analyzed in cells treated with SB-431542. (C) ET-1 mRNA expression was investigated using RT-qPCR to detect and quantify the level of transcripts. Values are represented as fold induction with respect to untreated cells. (D) Accumulation of ET-1 peptide in the extracellular medium was analyzed by specific ELISA and expressed as fmol/well. (E) ET-1 promoter activity was estimated by luminometry and values expressed as fold induction with respect to the corresponding control in the absence of TGF- (mean ± s.d., n=3).
|
